Damora Therapeutics, Inc.
DMRA
$31.04
$0.311.01%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -1,483.86% | -1,171.09% | -878.77% | 25.17% | 34.74% |
| Total Depreciation and Amortization | 317.39% | 3.30% | -81.22% | -105.82% | -97.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5,672.51% | 4,410.58% | 3,383.87% | -32.63% | -27.93% |
| Change in Net Operating Assets | 53,589.13% | 2,647.62% | 788.56% | 110.27% | 99.54% |
| Cash from Operations | -235.63% | -64.52% | 63.88% | 51.40% | 55.74% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | -100.00% |
| Cash from Investing | -- | -389.57% | -249.13% | -100.00% | -100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | -- | -- |
| Foreign Exchange rate Adjustments | -112.58% | 1,846.15% | 322.40% | -70.62% | 232.61% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,291.80% | 5,792.31% | 3,439.49% | -255.06% | -13,358.51% |